- Molecular NameQuinupristin
- SynonymNA
- Weight1022.24
- Drugbank_IDDB01369
- ACS_NO126602-89-9
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)N/A
- pkaN/A
- LogD (pH=7, predicted)N/A
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)N/A
- LogSw (predicted, AB/LogsW2.0)N/A
- Sw (mg/ml) (predicted, ACD/Labs)N/A
- No.of HBond DonorsN/A
- No.of HBond AcceptorsN/A
- No.of Rotatable BondsN/A
- TPSAN/A
- StatusFDA approved
- AdministrationN/A
- Pharmacologya combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding66.5
- Volume of distribution (VD)0.45 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIn vitro, the transformation of the parent drugs into their major active metabolites occurs by non-enzymatic reactions and is not dependent on cytochrome-P450 or glutathione-transferase enzyme activities. Fecal excretion constitutes the main elimination route for both parent drugs and their metabolites (75-77% of dose). Urinary excretion accounts for approximately 15% of the quinupristin and 19% of the dalfopristin dose. Preclinical data in rats have demonstrated that approximately 80% of the dose is excreted in the bile and suggest that in man, biliary excretion is probably the principal route for fecal elimination.
- Half life3.1 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityAdverse reactions with an incidence of more than 1% and possibly or probably related to Synercid administration include: infusion site reactions, nausea, vomiting, diarrhea, trombophlebitis, rash, headache, pruritis, pain.
- LD50 (rat)N/A
- LD50 (mouse)N/A